Predicting Quality of Life Based on Humor Style

Humor is a multifaceted construct commonly used in daily life. For centuries philosophers, healers, and religious figures have extolled humor as the “best medicine” for both the body and the mind. Recent research has shown humor can be adaptive or maladaptive (i.e., contribute to or subtract from well-being; Martin, Puhlik-Doris, Larsen, Gray, & Weir, 2003). Empirical evidence supporting these claims for humor and physical health has been inconsistent; however, new evidence suggests there may indeed be a connection (Martin, 2001; Martin et al., 2003). At the same time, previous research has consistently supported the notion that using humor is related to psychological health. Findings such as these have implications beyond one’s physical and mental health; these findings also have implications on one’s quality of life. Much like the notion of humor, quality of life is a difficult concept to define succinctly. Quality of life contains several domains including physical health, mental health, social status, and environmental elements (Skevington, Lotfy, & O’Connell, 2004). Previous research has suggested a link between humor and quality of life. Adaptive humor is positively correlated with indicators of psychological health, e.g. self-esteem (e.g., Stieger, Formann, & Burger, 2011) while maladaptive humor has been positively correlated with indicators of psychological distress, e.g. depression (Hugelshofer, Kwon, Reff, & Olson, 2006). To date, researchers have not studied humor and quality of life directly so the primary purpose of this study was to explore how well humor styles predict quality of life. To explore this predictive relationship, students from an introductory psychology class at a mid-size university were recruited to participate in this study. It was hypothesized that the adaptive humor styles would positively predict quality of life while the maladaptive humor styles would negatively predict quality of life. Stepwise regression models found partial support for the hypotheses. Implications and future directions are discussed

Gas in merging galaxies

We present observations of the neutral hydrogen, ionized hydrogen, and starlight of galaxies chosen from the 'Toomre Sequence' of merging galaxies. This sequence is meant to represent the progressive stages of the merger of two disk galaxies into a single elliptical-like remnant. The galaxies in this study span the full range of this sequence. The stars and atomic gas are very differently distributed, with the stars more widely distributed at early stages, and the gas much more widely distributed at later stages. Large quantities of neutral gas are sent to large radii (greater than or approximately equal to 100 h(exp -1) kpc), and still persist even after the central remnant has relaxed to an r(sup 1/4) light profile. There are a few times 10(exp 9) solar masses h(exp -2) of both molecular and atomic gas in each of these systems. Throughout the different stages, about half of the total gas mass lies within the galaxies' optical bodies. The fraction of this mass that is in neutral hydrogen drops rapidly in the later stage mergers, suggesting that atomic gas is processed into molecular gas, stars, and hot gas during the merger and resulting starburst. Star formation occurs at all stages of the interaction, both within the tails and in the central bodies. In the early stages, the H(alpha) shows many arcs and plumes. In the late stages, there are large H 2 regions in the tails which are associated with large quantities of neutral hydrogen. There is always a very good correlation between optical, H(alpha), and H1 peaks, with N(sub H1) greater than or approximately equal 3 x 10(exp 20) cm(exp -2) at the location of the H2 regions in the tails

Effect of Gemcitabine based chemotherapy on the immunogenicity of pancreatic tumour cells and T-cells.

PURPOSE: Chemotherapy for advanced pancreatic cancer has limited efficacy due to the difficultly of treating established tumours and the evolution of tumour resistance. Chemotherapies for pancreatic cancer are typically studied for their cytotoxic properties rather than for their ability to increase the immunogenicity of pancreatic tumour cells. In this study Gemcitabine in combination with immune modulatory chemotherapies Oxaliplatin, zoledronic acid and pomalidomide was studied to determine how combination therapy alters the immunogenicity of pancreatic tumour cell lines and subsequent T-cell responses. METHODS: Pancreatic tumour cell lines were stimulated with the chemotherapeutic agents and markers of immune recognition were assessed. The effect of chemotherapeutic agents on DC function was measured using uptake of CFSE-stained PANC-1 cells, changes in markers of maturation and their ability to activate CD8+ T-cells. The effect of chemotherapeutic agents on T-cell priming prior to activation using anti-CD3 and anti-CD28 antibodies was determined by measuring IFN-γ expression and Annexin V staining using flow cytometry. RESULTS: These agents demonstrate both additive and inhibitory properties on a range of markers of immunogenicity. Gemcitabine was notable for its ability to induce the upregulation of human leukocyte antigen and checkpoints on pancreatic tumour cell lines whilst inhibiting T-cell activation. Pomalidomide demonstrated immune modulatory properties on dendritic cells and T-cells, even in the presence of gemcitabine. DISCUSSION: These data highlight the complex interactions of different agents in the modulation of tumour immunogenicity and immune cell activation and emphasise the complexity in rationally designing chemo immunogenic combinations for use with immunotherapy

CD34+ Hematopoietic Progenitor Cell Selection of Bone Marrow Grafts for Autologous Transplantation in Pediatric Patients

AbstractCD34+-selection of hematopoietic grafts for patients undergoing autologous hematopoietic stem cell transplantation (HSCT) is frequently used to obtain a tumor-free graft. The majority of published experience is with peripheral blood stem cell (PBSC) products; only scant information has been published on bone marrow (BM) grafts. We reviewed our experience using CD34+ selection of BM grafts in children undergoing autologous BM transplantation. After obtaining institutional approval, we performed a retrospective review of the medical records of patients who underwent autologous stem cell collection at St. Jude. From January 1, 1999, to December 31, 2003, 373 patients underwent autologous HSCT; 131 received marrow grafts, 237 received PBSC grafts, and 5 received a combination. Seventeen patients underwent BM harvests for CD34+ selection of their stem cell grafts. Sixteen patients received 19 CD34 purified grafts processed on the Isolex 300i Magnetic Cell Selection System® device. Four patients were not included in the engraftment analysis as 1 did not receive the collected product, 1 received a tandem product, and 2 received products that were composed of 2 or 3 combined purified products. Following selection, marrow grafts contained a median of 1.4 × 106 CD34+ cells/kg (range: 0.09-8.3 × 106/kg) and a median of 0.014 ×108 total nucleated cell cells/kg (range: 0.001-0.09 × 108/kg). The median CD34% recovery was 30.9% (range: 9.3%-57.1%), with the median CD34 purity being 95.5% (range: 62.2%-98.8%). All patients engrafted. The median time to absolute neutrophil count ≥500/mm3 was 19 days (range: 12-35 days), and to platelet recovery was 28 days (range 18-37 days). No patient died from transplant-related complications. Our study demonstrates that CD34+-selection of marrow grafts is feasible, and these grafts are able to successfully reconstitute hematopoiesis in patients undergoing autologous BMT

Outcomes following autologous hematopoietic stem cell transplant for patients with relapsed Wilms' tumor: a CIBMTR retrospective analysis.

Despite the marked improvement in the overall survival (OS) for patients diagnosed with Wilms' tumor (WT), the outcomes for those who experience relapse have remained disappointing. We describe the outcomes of 253 patients with relapsed WT who received high-dose chemotherapy (HDT) followed by autologous hematopoietic stem cell transplant (HCT) between 1990 and 2013, and were reported to the Center for International Blood and Marrow Transplantation Research. The 5-year estimates for event-free survival (EFS) and OS were 36% (95% confidence interval (CI); 29-43%) and 45% (95 CI; 38-51%), respectively. Relapse of primary disease was the cause of death in 81% of the population. EFS, OS, relapse and transplant-related mortality showed no significant differences when broken down by disease status at transplant, time from diagnosis to transplant, year of transplant or conditioning regimen. Our data suggest that HDT followed by autologous HCT for relapsed WT is well tolerated and outcomes are similar to those reported in the literature. As attempts to conduct a randomized trial comparing maintenance chemotherapy with consolidation versus HDT followed by stem cell transplant have failed, one should balance the potential benefits with the yet unknown long-term risks. As disease recurrence continues to be the most common cause of death, future research should focus on the development of consolidation therapies for those patients achieving complete response to therapy

Outcomes following autologous hematopoietic stem cell transplant for patients with relapsed Wilms’ tumor: a CIBMTR retrospective analysis

Despite the dramatic improvement in the overall survival for patients diagnosed with Wilms’ tumor (WT), the outcomes for those that experience relapse have remained disappointing. We describe the outcomes of 253 patients with relapsed WT who received high-dose chemotherapy (HDT) followed by autologous hematopoietic stem cell transplant (HCT) between 1990 and 2013, and reported to the Center for International Blood and Marrow Transplantation Research (CIBMTR). The 5-year estimates for event free survival (EFS) and overall survival (OS) were 36% (95% CI; 29 – 43%) and 45% (95% CI; 38 – 51%) respectively. Relapse of primary disease was the cause of death in 81% of the population. EFS, OS, relapse and transplant-related mortality (TRM) showed no significant differences when broken down by disease status at transplant, time from diagnosis to transplant, year of transplant or conditioning regimen. Our data suggest that HDT followed by autologous HCT for relapsed WT is well tolerated and outcomes are similar to those reported in the literature. Since attempts to conduct a randomized trial comparing maintenance chemotherapy with consolidation versus high-dose chemotherapy followed by stem cell transplant have failed, one should balance the potential benefits with the yet unknown long-term risks. Since disease recurrence continues to be the most common cause of death, future research should focus on the development of consolidation therapies for those patients achieving complete response to therapy

Total and Active Rabbit Antithymocyte Globulin (rATG;Thymoglobulin®) Pharmacokinetics in Pediatric Patients Undergoing Unrelated Donor Bone Marrow Transplantation

AbstractRabbit antithymocyte globulin (rATG; Thymoglobulin®) is currently used to prevent or treat graft-versus-host disease (GVHD) during hematopoietic stem cell transplantation (HSCT). The dose and schedule of rATG as part of the preparative regimen for unrelated donor (URD) bone marrow transplantation (BMT) have not been optimized in pediatric patients. We conducted a prospective study of 13 pediatric patients with hematologic malignancies undergoing URD BMT at St. Jude Children's Research Hospital from October 2003 to March 2005, to determine the pharmacokinetics and toxicities of active and total rATG. The conditioning regimen comprised total body irradiation (TBI), thiotepa, and cyclophosphamide (Cy); cyclosporine (CsA) and methotrexate (MTX) were administered as GVHD prophylaxis. Patients received a total dose of 10 mg/kg rATG, and serial blood samples were assayed for total rATG by enzyme linked immunosorbent assay (ELISA) and active rATG by florescein activated cell sorting (FACS). We found that our weight-based dosing regimen for rATG was effective and well tolerated by patients. The half-lives of total and active rATG were comparable to those from previous studies, and despite high doses our patients had low maximum concentrations of active and total rATG. There were no occurrences of grade iii-iv GVHD even in patients having low peak rATG levels, and the overall incidence of grade II GVHD was only 15%. None of the patients had serious infections following transplantation. These data support the use of a 10 mg/kg dose of rATG in children with hematologic malignancies because it can be administered without increasing the risk of graft rejection, or serious infection in pediatric patients with a low rate of GVHD. These conclusions may not apply to patients with nonmalignant disorders

Staphylococcus aureus bloodstream infection due to contaminated hematopoietic stem-cell graft

To the Editor—The Foundation for the Accreditation of Cellular Therapy and the American Association of Blood Banks publish guidelines to ensure the quality and safety of hematopoietic stem-cell (HSC) products. These HSC products are generally cultured after procurement by the collection facility and following processing at the transplant center. Reported contamination rates of HSC grafts range from 1% to 45%. The clinical significance of infusion of contaminated HSC products is unclear. When fresh products are used, contamination is often not identified prior to HSC infusion. Bacterial contamination is not an absolute contraindication to HSC infusion, as options are limited following a myeloablative preparative regimen. In a review of 12 studies, 91% of contaminated grafts contained bacterial species of low pathogenicity (eg, Staphylococcus epidermidis and Propionibacterium acnes). Of 26 patients who received grafts contaminated with highly pathogenic bacteria (eg, S. aureus), none developed symptoms or had a positive culture matching an organism found in the HSC graft. In prior reports of infections putatively caused by graft contamination, confirmation that the graft was the source of infection was based solely on the finding of identical species. Contrary to these prior reports, we present a case of catheter-related bloodstream infection with methicillin-susceptible S. aureus due to a contaminated HSC graft in which pulsed-field gel electrophoresis (PFGE) confirmed that the graft and patient isolates were identical